Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells

Atherosclerosis
Fumiaki OsakiKozo Hashimoto

Abstract

Human serum paraoxonase 1 (PON1) is associated with high-density lipoprotein, and inhibits oxidative modification of low-density lipoprotein in vitro. Therefore, PON1 is supposed to protect against atherosclerosis in vivo. In this study, we investigated the direct effect of Sp1 on PON1 transcription in HepG2 cells using a reporter gene assay. A deletion analysis of the PON1 upstream region revealed that dominant promoter elements were present within a sequence between -269 and -97bp, which contained a consensus binding site for Sp1, and an electrophoretic mobility shift analysis (EMSA) indicated the Sp1 binding to the upstream sequence. In accordance with this, overexpression of Sp1 dramatically enhanced PON1 promoter activity, and the Sp1 inhibitor mithramycin inhibited Sp1-induced promoter activation in a dose-dependent manner. The basal promoter activity was also enhanced by phorbol 12-myristate 13-acetate (PMA), and synergistic promoter activation was observed when Sp1-transfected cells were treated with PMA. The PMA-induced promoter activation was inhibited by mithramycin. In addition, overexpression of the dominant negative version of PKCalpha or zeta, significantly reduced PON1 promoter activity. These data suggest that ...Continue Reading

References

Jan 25, 1994·Biochemistry·G J KelsoJ A Harmony
Jun 1, 1993·Chemico-biological Interactions·M I MacknessP N Durrington
Apr 15, 1993·The Biochemical Journal·H Hug, T F Sarre
Mar 29, 1996·Clinica Chimica Acta; International Journal of Clinical Chemistry·R SchiavonG Guidi
Jun 26, 1998·The Biochemical Journal·H Mellor, P J Parker
Sep 7, 2000·The Journal of Biological Chemistry·T TakaharaH Akanuma
Nov 25, 2000·Metabolism: Clinical and Experimental·M InoueK Hashimoto
Feb 24, 2001·Pharmacogenetics·V H BrophyC E Furlong
Aug 2, 2001·Journal of Atherosclerosis and Thrombosis·T ItaharaK Hashimoto
Sep 13, 2002·Journal of Atherosclerosis and Thrombosis·Tadashi SuehiroKozo Hashimoto
Mar 20, 2003·Molecular Pharmacology·Cédric GouédardYannick Morel

❮ Previous
Next ❯

Citations

Dec 17, 2009·Genes & Nutrition·Raj LakshmanSamir Zakhari
Aug 27, 2011·Antioxidants & Redox Signaling·Zhi-Gang SheDe-Pei Liu
May 11, 2013·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Bo GaoSidong Xiong
Jul 2, 2005·Current Opinion in Lipidology·Michael Aviram, Mira Rosenblat
Mar 16, 2012·The American Journal of Chinese Medicine·Chi-Chih ChengShih-Lan Hsu
Nov 27, 2008·American Journal of Physiology. Gastrointestinal and Liver Physiology·Seema SaksenaPradeep K Dudeja
May 2, 2012·Journal of Lipids·Bianca Fuhrman
Aug 17, 2012·Journal of Lipid Research·Daniel S KimGail P Jarvik
Jun 8, 2012·Journal of Cardiovascular Medicine·Muiruri MachariaTandi E Matsha
Jul 1, 2014·PloS One·Jagan Mohan JasnaNarayanasamy Angayarkanni
Nov 28, 2012·North American Journal of Medical Sciences·Dmitry LitvinovMahdi Garelnabi
Jan 1, 2008·Nanoscale Research Letters·Daisuke AsaiYoshiki Katayama
Jan 23, 2010·Metabolism: Clinical and Experimental·Kaoru AriiYoshio Terada
Jan 15, 2009·Biochemical and Biophysical Research Communications·Maokai GongRaj M Lakshman
Nov 18, 2008·Metabolism: Clinical and Experimental·Yukio IkedaKozo Hashimoto
May 19, 2007·Molecular and Cellular Endocrinology·Shojiro InadaKozo Hashimoto
Apr 22, 2008·Proteomics·Jeong-Hun KangYoshiki Katayama
Mar 13, 2014·Journal of Biochemical and Molecular Toxicology·Mary Beth DailJanice E Chambers
Nov 26, 2010·Biochemical Pharmacology·Lucio G CostaClement E Furlong
Jan 26, 2010·Analytical Biochemistry·Syed AhmadJohn E Scott
Jul 3, 2009·Drug Metabolism and Pharmacokinetics·Atsushi MiyajimaKan Chiba
Mar 12, 2015·Drug Metabolism and Pharmacokinetics·Shingo OdaMiki Nakajima
Aug 23, 2019·International Journal of Molecular Sciences·Maria João MenesesMaria Paula Macedo
Dec 29, 2018·Current Neuropharmacology·Estefania Gastaldello MoreiraMichael Maes
Jan 5, 2017·Toxicological Sciences : an Official Journal of the Society of Toxicology·Emma C Bowers, Shaun D McCullough
Mar 7, 2021·International Journal of Molecular Sciences·Anna Wysocka, Agnieszka Zwolak

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.